Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hypoglycemia 1 endocrinologydiseases
metformin 2 endocrinologydiseasesdrugs
obesity 2 endocrinologydiseases
pioglitazone 11 endocrinologydiseasesdrugs
rosiglitazone 5 endocrinologydiseasesdrugs
diabetes mellitus 2 endocrinologydiseases
hyperglycemia 1 endocrinologydiseases
hyperinsulinemia 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
metformin 15448 comparator group (no TZDs) received a variety of ADMs, including insulin, insulin analogs, sulfonylureas, metformin , or other hypoglycemia agents, which may have inherent cancer-modifying effects. For example, insulin
metformin 15650 example, insulin or sulfonylurea has been reported to be associated with an increased risk of CRC, whereas metformin may be correlated with a decreased CRC risk.[[56]] This may result in an overestimation or underestimation
pioglitazone 1638 population (RR = 0.94, 95% CI = 0.88–1.01, P = 0.08). CRC risk was significantly modified with non- pioglitazone TZD use (RR = 0.88, 95% CI = 0.82–0.95, P = 0.00), but not with pioglitazone use (RR = 0.95, 95% CI
pioglitazone 1717 significantly modified with non-pioglitazone TZD use (RR = 0.88, 95% CI = 0.82–0.95, P = 0.00), but not with pioglitazone use (RR = 0.95, 95% CI = 0.89–1.01, P = 0.11). No significant difference was observed with cancer
pioglitazone 4904 TZDs and CRC risk, using the terms “thiazolidinediones,” “glitazones,” “troglitazone,” “ pioglitazone ,” “rosiglitazone,” “colorectal,” “colon,” “rectum,” “cancer,” “neoplasm,”
pioglitazone 9862 patients with DM; RR = 0.40, 95% CI = 0.29–0.53, P = 0.00).[[36]] When referred to drug type, non- pioglitazone TZD showed a modest protective effect on CRC risk in diabetic patients (n = 2 studies, 12,268 CRC cases
pioglitazone 10102 with DM; RR = 0.88, 95% CI = 0.82–0.95, P = 0.00);[[37][38]] however, such effect was not found in pioglitazone group (n = 3 studies, 14,969 CRC cases in 1,974,120 patients with DM; RR = 0.95, 95% CI = 0.89–1.01,
pioglitazone 13403 this issue.As far as drug type is concerned, the apparent protection from malignancy conferred by non- pioglitazone TZD use (mainly rosiglitazone) was detectable in our study (a 12% reduction in CRC risk). On the other
pioglitazone 13525 (mainly rosiglitazone) was detectable in our study (a 12% reduction in CRC risk). On the other hand, pioglitazone did not protect from malignancy. The observed discrepancies between the two types of TZDs may be due
pioglitazone 13868 apoptotic-inducing, and differentiation-stimulating effects in different malignancies,[[10]] whereas pioglitazone has dual PPAR-α-γ activities, which have shown carcinogenic effects in animal models, especially for
pioglitazone 14266 recommended in current diabetes guidelines,[[51]] because concerns over bladder cancer conferred by pioglitazone have largely been allayed by recent evidence.[[52][53][54]] The side effects of rosiglitazone have limited
pioglitazone 14587 the positive consequences on CRC risk, the potential implications on the risk/benefit analysis of non- pioglitazone TZDs use should be revaluated.We could not establish whether TZDs are differentially associated with
pioglitazone 16224 retrospectively historical medical data. Thus, a complete elimination of bias on details was impossible. Third, pioglitazone and rosiglitazone are two different drugs for cancer risk. Pooling them together creates an obvious
rosiglitazone 4924 using the terms “thiazolidinediones,” “glitazones,” “troglitazone,” “pioglitazone,” “ rosiglitazone ,” “colorectal,” “colon,” “rectum,” “cancer,” “neoplasm,” and “risk.” The reference
rosiglitazone 13432 is concerned, the apparent protection from malignancy conferred by non-pioglitazone TZD use (mainly rosiglitazone ) was detectable in our study (a 12% reduction in CRC risk). On the other hand, pioglitazone did not
rosiglitazone 13696 discrepancies between the two types of TZDs may be due to the differences at biologic level. Pharmacologically, rosiglitazone has PPAR-γ activity, which has shown antiproliferative, apoptotic-inducing, and differentiation-stimulating
rosiglitazone 14359 conferred by pioglitazone have largely been allayed by recent evidence.[[52][53][54]] The side effects of rosiglitazone have limited its use, including weight gain, bone fracture, chronic edema, and heart failure.[[55]]
rosiglitazone 16241 medical data. Thus, a complete elimination of bias on details was impossible. Third, pioglitazone and rosiglitazone are two different drugs for cancer risk. Pooling them together creates an obvious lack of drug-specific
Select Disease Character Offset Disease Term Instance
diabetes mellitus 167 Saudi Gastroenterology AssociationThiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus : A meta-analysisYang LiuPiao-Piao JinXue-Cheng SunTing-Ting HuDepartment of Gastroenterology and Hepatology,
diabetes mellitus 668 colorectal cancer (CRC). This study aimed to evaluate the effect of TZDs on CRC risk in patients with diabetes mellitus (DM).Patients and Methods:A systematic search of electronic databases was performed for studies evaluating
hyperglycemia 2629 carcinogenesis through complex processes. The mechanisms underlying may possibly be related to hyperinsulinemia, hyperglycemia , or an obesity-associated chronic inflammation, which may contribute to an increased cellular proliferation
hyperinsulinemia 2611 CRC carcinogenesis through complex processes. The mechanisms underlying may possibly be related to hyperinsulinemia , hyperglycemia, or an obesity-associated chronic inflammation, which may contribute to an increased
hypoglycemia 15468 received a variety of ADMs, including insulin, insulin analogs, sulfonylureas, metformin, or other hypoglycemia agents, which may have inherent cancer-modifying effects. For example, insulin or sulfonylurea has been
obesity 2650 processes. The mechanisms underlying may possibly be related to hyperinsulinemia, hyperglycemia, or an obesity -associated chronic inflammation, which may contribute to an increased cellular proliferation and tumor
obesity 12650 lead to the differential association in the two populations. Besides, a higher prevalence of central obesity is exhibited in some Asian populations, who are supposed to be more insulin resistant and more responsive

You must be authorized to submit a review.